Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06876649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

StatusRecruiting
PhasePhase 4
Started2025-05-20
View on ClinicalTrials.gov ↗
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Amendment record

Amended 14 times since 2025-03-13; most recent filed 2026-02-27. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-02-27
Amendment Study Status, Contacts/Locations v14
2026-01-19
Amendment Study Status, Contacts/Locations v13
2025-12-12
Amendment Study Identification, Study Status, Contacts/Locations v12
2025-12-08
Amendment Study Status, Contacts/Locations v11
2025-11-19
Amendment Study Status, Contacts/Locations v10
2025-11-05
Amendment Study Status, Contacts/Locations v9
2025-10-10
Amendment Study Status, Contacts/Locations v8
2025-09-25
Amendment Study Status, Contacts/Locations v7
2025-09-05
Amendment Study Status, Contacts/Locations v6
2025-08-18
Amendment Study Status, Study Design, Outcome Measures, Eligibility v5
2025-07-18
Amendment Study Status, Contacts/Locations v4
2025-06-18
Amendment Not Yet RecruitingRecruiting Study Status, Contacts/Locations v3
2025-05-27
Amendment Study Status, Contacts/Locations v2
2025-04-18
Amendment Study Status, Contacts/Locations v1
2025-03-13
Original filing
Trial Details
NCT Number NCT06876649
Lead Sponsor Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Enrollment 787 participants
Start Date 2025-05-20
Primary Completion 2030-05 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-02